BioSpace News Archive

Sparrow Pharmaceuticals presented pharmacology data during an online poster session on SPI-62, a HSD-1 inhibitor, at the American College of Rheumatology Convergence 2022 meeting.

To improve the health of a community, the first step is to identify its most pressing needs.

Sofusa®, a wholly-owned division of Sorrento Therapeutics, announced that it will host a virtual Key Opinion Leader panel discussion titled “Empowering the Lymphatics: Unleashing the Potential of Biologics that Target the Immune System” to be held on Thursday, November 17, 2022 at 11:30 AM EST.

Innovent Biologics, Inc. presented the updated results of IBI351 from a phase Ia clinical trial at the 2022 Chinese Society of Clinical Oncology Annual Meeting.

Nuance Pharma announces the Center for Drug Evaluation has approved its Investigational New Drug application supporting its pivotal phase III clinical trial of MVA-BN RSV vaccine against respiratory syncytial virus in adults in mainland China.

After sun exposure, people with systemic lupus erythematosus frequently develop skin rashes, which often are accompanied by a flare of their overall disease.

Ascendis Pharma A/S announced positive topline results from the ACcomplisH Trial, its Phase 2 randomized, double-blind, placebo-controlled, dose-escalation trial evaluating the safety and efficacy of once-weekly TransCon CNP compared to placebo in children with achondroplasia aged 2 to 10 years old.

Akeso, Biopharma announced that the Center for Drug Evaluation of the China National Medical Products Administration has granted Breakthrough Therapy Designation for Ivonescimab combined with docetaxel for the treatment of locally advanced or metastatic Non-Small-Cell Lung Carcinoma patients who failed to respond to prior PD-1 inhibitor combined with platinum-based doublet chemotherapy.

InnoCare Pharma, a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced 2022 third quarter results and latest corporate development.

Shanghai Stock Exchange listed company HitGen Inc. announced that it has entered into a research collaboration agreement with DAEWOONG PHARMACEUTICAL Co., Ltd, a global healthcare group in the Republic of Korea, dedicated to improving the quality of patients’ lives.